New American College of Rheumatology Guidelines for Lupus Nephritis Recommend Triple Therapy, Highlighting a Shift in Current Treatment Practices, According to Spherix Global Insights
January 08, 2025 15:35 ET
|
Spherix Global Insights
EXTON, PA, Jan. 08, 2025 (GLOBE NEWSWIRE) -- At the 2024 American College of Rheumatology (ACR) Convergence, the organization unveiled updated guidelines for the screening, treatment, and management...
Inflation Reduction Act Likely to Shape Specialty Prescribing Decisions in 2025, According to Spherix Global Insights
December 10, 2024 09:59 ET
|
Spherix Global Insights
EXTON, PA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- In 2022, the U.S. Congress enacted the Inflation Reduction Act (IRA), a landmark piece of legislation aimed at addressing various national priorities,...
Patient Chart Audit Reveals Changing Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Dynamics As New Competition Challenges Alexion/Astra Zeneca's Soliris and Ultomiris
November 21, 2024 09:27 ET
|
Spherix Global Insights
EXTON, PA, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights has released its first annual chart audit study in hematology, Patient Chart Dynamix™ : Paroxysmal Nocturnal Hemoglobinuria (PNH)...
Hope on the Horizon: Nephrologists Emphasize Need for Innovative C3G Treatments as Novartis and Apellis Prepare Therapies for FDA Submission
November 15, 2024 13:15 ET
|
Spherix Global Insights
EXTON, PA, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare, progressive kidney disease characterized by inflammation and kidney damage. Patients with C3G often...
Tremfya's Promising Debut Boosts Momentum for IL-23 Class in Ulcerative Colitis Treatment, According to Spherix Global Insights
November 15, 2024 09:38 ET
|
Spherix Global Insights
EXTON, PA, Nov. 15, 2024 (GLOBE NEWSWIRE) -- In what has been a transformative year for ulcerative colitis (UC) treatment, the IL-23 class has solidified its role as a key therapeutic treatment...
Spherix Global Insights Focuses on Earlier use of Advanced Treatments in Hidradenitis Suppurativa (HS) as a Catalyst for Better Patient Outcomes
November 07, 2024 17:09 ET
|
Spherix Global Insights
EXTON, PA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights has published a new white paper, Earlier Diagnosis and Treatment: The Key to Better Outcomes in Hidradenitis Suppurativa,...
Critical Gaps in FSGS Treatment Highlight Need for New Therapies, with Pipeline Assets from Travere, Vertex, and Dimerix Poised to Address Unmet Needs
November 01, 2024 09:17 ET
|
Spherix Global Insights
EXTON, PA, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Focal segmental glomerulosclerosis (FSGS), one of the most common glomerular diseases seen by nephrologists, ranks among the top three rare kidney...
US Rheumatologists and Dermatologists Report Over Half of their Dermatomyositis Patients Not Optimally Managed, According to Spherix Global Insights
October 18, 2024 10:56 ET
|
Spherix Global Insights
EXTON, PA, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Dermatomyositis (DM) is a rare inflammatory disease characterized by muscle weakness and a distinctive skin rash. Currently, the standard of care...
Shifts in the Psoriasis Market Suggest Strong Potential for Emerging Oral Therapies
October 16, 2024 14:48 ET
|
Spherix Global Insights
EXTON, PA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Biologics have long been the cornerstone of psoriasis (PsO) treatment, valued for their proven efficacy and safety. However, the growing demand for...
Hemophilia Markets Poised for Evolution as Competitive Dynamics between Hemlibra (Roche/Genentech) and Altuviiio (Sanofi) Intensify and Hympavzi (Pfizer) Receives Approval, According to Spherix Global Insights
October 14, 2024 12:33 ET
|
Spherix Global Insights
EXTON, PA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Hemophilia, a genetic disorder that impairs blood clotting, affects thousands of people worldwide. The treatment landscape is rapidly evolving, fueled by...